Chiasma Inc(CHMA) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.

Current Price

$3.98

RSI

85.935

Beta:

1.380584

March 04, 2021
-21M

-68.127 %
-80.131 %

$-4,808,000
$-59,000
$31,000
$-212,000
$-340,000
$0
-98.773 %
-152.542 %
783.871 %
60.377 %
0.000 %

$-74,695,000
$-36,036,000
$-31,292,000
$-27,416,000
$-60,764,000
$-35,747,000
-51.756 %
-13.165 %
-12.387 %
121.637 %
-41.171 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.